Guidelines and algorithms for the use of methylphenidate in children with Attention-Deficit/ Hyperactivity Disorder
- PMID: 12685523
- DOI: 10.1177/070674370200601s11
Guidelines and algorithms for the use of methylphenidate in children with Attention-Deficit/ Hyperactivity Disorder
Abstract
Objective: To review published algorithms for guiding the use of methylphenidate (MPH) in the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children and adolescents.
Methods: A consensus roundtable of 12 experts was convened to review the evidence for the safety and efficacy of MPH in the treatment of ADHD, as well as the published algorithms and practice guidelines for using MPH. The experts reviewed the algorithms for practicality and acceptability by clinicians.
Results: Algorithms that included MPH commonly selected it as the initial medication to be employed in the treatment of children with ADHD. Factors involved included its high efficacy, good safety record, and the ubiquitous nature of its appearance in the ADHD treatment literature.
Conclusions: MPH should be considered as the first medication to be used in a treatment algorithm for children and adolescents with ADHD.
Similar articles
-
Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: Meta-analysis based on head-to-head trials.J Clin Exp Neuropsychol. 2017 Nov;39(9):854-865. doi: 10.1080/13803395.2016.1273320. Epub 2017 Jan 4. J Clin Exp Neuropsychol. 2017. PMID: 28052720
-
Effects of methylphenidate on body index and physical fitness in Korean children with attention deficit hyperactivity disorder.Hum Psychopharmacol. 2016 Mar;31(2):76-82. doi: 10.1002/hup.2514. Epub 2016 Jan 12. Hum Psychopharmacol. 2016. PMID: 26756111
-
Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.CNS Drugs. 2017 Nov;31(11):999-1014. doi: 10.1007/s40263-017-0468-2. CNS Drugs. 2017. PMID: 28980198 Free PMC article.
-
Methylphenidate in Adults with Attention Deficit Hyperactivity Disorder and Substance Use Disorders.Curr Pharm Des. 2015;21(23):3359-66. doi: 10.2174/1381612821666150619093254. Curr Pharm Des. 2015. PMID: 26088112 Review.
-
Responses to methylphenidate in Attention-Deficit/Hyperactivity Disorder and normal children: update 2002.J Atten Disord. 2002;6 Suppl 1:S57-60. doi: 10.1177/070674370200601s07. J Atten Disord. 2002. PMID: 12685519 Review.
Cited by
-
The Effects of Methylphenidate on Ventricular Repolarization Parameters in Children with Attention-Deficit Hyperactivity Disorder.Alpha Psychiatry. 2023 Sep 1;24(5):174-179. doi: 10.5152/alphapsychiatry.2023.231185. eCollection 2023 Sep. Alpha Psychiatry. 2023. PMID: 38105780 Free PMC article.
-
Effects of the DRD4 -521 C/T SNP on Local Neural Activity and Functional Connectivity in Children With ADHD.Front Psychiatry. 2022 Jan 6;12:785464. doi: 10.3389/fpsyt.2021.785464. eCollection 2021. Front Psychiatry. 2022. PMID: 35069289 Free PMC article.
-
Paternal exposure to a common pharmaceutical (Ritalin) has transgenerational effects on the behaviour of Trinidadian guppies.Sci Rep. 2021 Feb 17;11(1):3985. doi: 10.1038/s41598-021-83448-x. Sci Rep. 2021. PMID: 33597600 Free PMC article.
-
Chronic oral methylphenidate treatment increases microglial activation in rats.J Neural Transm (Vienna). 2018 Dec;125(12):1867-1875. doi: 10.1007/s00702-018-1931-z. Epub 2018 Sep 20. J Neural Transm (Vienna). 2018. PMID: 30238340 Free PMC article.
-
Integrative genomic analysis of methylphenidate response in attention-deficit/hyperactivity disorder.Sci Rep. 2018 Jan 30;8(1):1881. doi: 10.1038/s41598-018-20194-7. Sci Rep. 2018. PMID: 29382897 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
